Navigation Links
Lilly Reports Third-Quarter 2011 Results
Date:10/20/2011

p>$

1,253.8

$

1,341.4

(7)%$

3,944.6

$

4,005.9

(2)%Earnings per share – basic and diluted

$

1.13

$

1.21

(7)%$

3.54

$

3.63

(2)%Dividends paid per share

$

.49

$

.49

0%$

1.47

$

1.47

0%Weighted-average shares
  outstanding (thousands) – basic1,113,8201,105,1731,113,3241,104,265Weighted-average shares
  outstanding (thousands) – diluted1,113,8411,105,1981,113,3471,104,290(a.)
The third quarter 2011 has been adjusted to eliminate a restructuring charge of $25.2 million (pretax), or $0.02 (after-tax).  The year-to-date 2011 financial statements have been adjusted to eliminate total restructuring charges of $233.8 million (pretax), or $0.18 (after-tax). These charges are related to severance costs from previously announced strategic actions that the company is taking to reduce its cost structure and global workforce. In addition, the year-to-date 2011 financial statements have been adjusted to eliminate a charge of $388.0 million (pretax), or $0.23 per share (after-tax), for acquired in-process research and development associated with the collaboration with Boehringer Ingelheim.(b.)
The third quarter 2010 has been adjusted to eliminate a restructuring charge of $59.5 million (pretax), or $0.03 (after-tax). The year-to-date 2010 financial statements have been adjusted to eliminate total restructuring charges of $113.0 million (pretax), or $0.07 (after-tax).  These charges are primarily related to severance costs from previously announced strategic actions that the company is taking to reduce its cost structure and global workforce. In addition, the year-to-date 2010 financial statements have been adjusted to eliminate a charge of $50.0 million (pretax), or $0.03 per share (after-tax), for acquired in-process research and development associated wi
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Lilly Declares Fourth-Quarter 2011 Dividend
2. Lilly Announces Changes in Senior Management
3. Lilly Confirms Date and Conference Call for Third-Quarter 2011 Financial Results Announcement
4. Lilly Improves Its Environmental Footprint in Business Operations and Helps Beautify Communities
5. Eli Lilly and Company Bringing Diabetes Education Program to the Annual Legislative Conference
6. Lilly Celebrates 17th Consecutive Year as One of Working Mother 100 Best Companies
7. Lilly Health Channel Debuts on YouTube
8. Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes
9. The American Diabetes Association and Eli Lilly and Company Encourage African Americans to Learn About Diabetes Through a Familiar Face
10. Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion
11. U.S. Court of Appeals Affirms Validity of Lillys Strattera Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  InnoPharma, Inc. today ... 10mg/vial (the generic equivalent of Zyprexa® injection), in Canada.  ... and disturbed behaviors in patients with schizophrenia or bipolar ... generic injectable drug, InnoPharma has entered into an agreement ... Canada will make, use, sell, market and distribute ...
(Date:7/30/2014)... Cynosure, Inc. (NASDAQ: CYNO ... non-invasive and minimally invasive applications, today announced that the Board ... and Chief Financial Officer Timothy W. Baker to ... will continue to serve as CFO and will take the ... Chairman and Chief Executive Officer. "Tim has ...
(Date:7/30/2014)... SAN DIEGO , July 30, 2014 /PRNewswire/ ... ) announced today that an article based on post-hoc analyses ... "Early Weight Loss While on Lorcaserin, Diet, and Exercise as ... in the online issue of Obesity , the official ... these analyses was to identify whether there is an early ...
Breaking Medicine Technology:InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
... Mass., Nov. 17 Decision Resources, one of the world,s ... finds that, driven by the continued dominance of opioids that ... cancer pain drug market will increase from $2.3 billion in ... France, Germany, Italy, Spain, the United Kingdom and Japan. , ...
... , DURHAM, N.C., Nov. 17 Oxygen ... the company has begun shipping Dermacyte(TM) Oxygen Concentrate Gel ... The shipments, which are going out today, cover orders ... milestone event for our company - actually shipping a ...
Cached Medicine Technology:The Cancer Pain Drug Market, Driven by the Continued Dominance of Opioids, Will Increase From $2.3 Billion in 2008 to $3.7 Billion in 2018 2Oxygen Biotherapeutics, Inc. Begins Shipping Cosmetic Product to Customers 2
(Date:7/30/2014)... well as evolutionary changes in a living organismhad been ... the genome. , However, recent studies have shown that ... that arise simultaneously and in close proximity to each ... in regions where chromosomal rearrangements take place. , The ... may one day lead to new cancer therapies, according ...
(Date:7/30/2014)... 30, 2014 Hamilton Facial Plastic ... its new Carmel office on July 30th. After months ... be moving to the state-of-the-art suite, located only steps ... space will allow for one-on-one patient comfort, shorter wait ... , Dr. Hamilton’s new office-suite will continue to ...
(Date:7/30/2014)... NJ. July 30, 2014. A new network of 25 ... Stroke Trials Network (NIH StrokeNet) is working to ... U.S. Despite advances of the last two decades, ... stroke causes death or disability for 795,000 Americans. The ... of the population. , To accelerate the pace ...
(Date:7/30/2014)... Over 630 doctors worldwide are now certified ... minimally invasive treatment for gum recession. Santa Barbara, CA ... peers to be the “father of microsurgery” in periodontics ... Pinhole Surgical Technique® training course at the Chao Pinhole ... of the American Academy of Periodontics (AAP) 2010 Master ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Children’s Hospital ... celebrate Safety Day from 4 p.m. to 7 p.m. ... (29580 7 Mile Road, Livonia, MI 48152). The event ... bike helmets, children’s activities, music, snacks and local public ... to the Children’s Hospital of Michigan Foundation. , ...
Breaking Medicine News(10 mins):Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2Health News:Periodontist Dr. Dennis Shanelec Comments On The Chao Pinhole Surgical Technique® Training Course 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 3Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 4
... guidelines show half to two-thirds of women of childbearing ... News) -- A new study says federal guidelines on ... the category of "obese." , U.S. guidelines determine who ... whether a person,s height and weight are proportional. The ...
... much control a person has over their own health outcomes. ... when doctor and patient attitudes on the issue match up, ... Published online and in the May issue of the ... of a growing body of evidence indicating that patient-physician compatibility ...
... fewer side effects, experts say, , WEDNESDAY, April 21 (HealthDay ... promise in early testing as a possible new treatment for ... It,s too early to tell if the drug actually works, ... federal approval to be prescribed to patients. Still, the drug ...
... power, according to Penn State researchers who will test ... to help them manage their disease. The project, ... Chris Sciamanna, professor, department of medicine, Penn State College ... Lung and Blood Institute as part of the National ...
... ... , ... (Vocus) April 21, 2010 -- SafeShot Technologies, LLC , a leader in safety ... Emeritus Professor of Surgery at Keck School of Medicine, University of Southern California. Dr. ...
... D.C. Women who have a breast density of 75 ... breast cancer that is four to five times greater than ... breast density one of the strongest biomarkers of breast cancer ... 101st Annual Meeting 2010, held in Washington, D.C., April 17-21, ...
Cached Medicine News:Health News:More U.S. Women May Be Obese Than Thought 2Health News:Patient-physician compatibility increases odds of following doctor's orders 2Health News:Patient-physician compatibility increases odds of following doctor's orders 3Health News:In Early Test, New Hepatitis C Drug Shows Promise 2Health News:Knowledge is power in Penn State blood pressure study 2Health News:SafeShot Technologies Names Dr. Robert W. Beart as New Chief Executive Officer 2Health News:SafeShot Technologies Names Dr. Robert W. Beart as New Chief Executive Officer 3Health News:Mammographic density and risk of breast cancer 2Health News:Mammographic density and risk of breast cancer 3Health News:Mammographic density and risk of breast cancer 4Health News:Mammographic density and risk of breast cancer 5
Subretinal Injection Cannula, Straight; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 35°....
Silicone Oil Cannula; 16g (1.40) x 8mm....
Injection Cannula, Straight; 20g (0.90) x 1" (25mm); Tip Extension: 5mm, 30g (0.30)....
...
Medicine Products: